Critical illness triggers profound molecular and cellular responses, including widespread chromatin accessibility changes that modulate gene expression and cellular function. This review synthesizes current evidence on the patterns, mechanisms, and clinical relevance of chromatin remodeling in critical illness, integrating insights from recent genomic studies and highlighting implications for diagnosis, risk stratification, and emerging therapies. Understanding these epigenetic shifts may inform precision medicine approaches and improve outcomes for critically ill patients.
Critical illness, encompassing conditions such as sepsis, acute respiratory distress syndrome (ARDS), and multi-organ dysfunction, is characterized by heterogeneous host responses at the molecular level. Recent advances in epigenomic profiling have revealed that chromatin accessibility—the degree to which DNA is exposed for transcription factor binding and gene regulation—undergoes dynamic changes during critical illness. These alterations influence key immune, metabolic, and reparative pathways, affecting disease progression and recovery. A deeper understanding of these chromatin changes can provide novel insights into disease pathogenesis and open new avenues for therapeutic intervention.
Critical illness represents a significant global health burden, affecting millions annually in intensive care settings. Sepsis alone accounts for over 11 million deaths each year worldwide. Despite advances in supportive care, mortality and long-term morbidity remain high due to unresolved pathophysiological mechanisms. Epigenetic dysregulation—including chromatin remodeling—has emerged as a key contributor to the persistent immune dysfunction and organ injury observed in survivors. The identification of chromatin accessibility changes across diverse populations highlights their ubiquitous role in mediating responses to acute physiological stress.
During critical illness, inflammatory mediators, hypoxia, and metabolic stress induce rapid chromatin remodeling within immune and non-immune cells. This is achieved through post-translational modifications of histones (e.g., acetylation, methylation) and the recruitment of chromatin remodelers, resulting in altered accessibility at promoters and enhancers of genes governing inflammation, metabolism, and cell survival. In sepsis, for example, monocytes and macrophages display a loss of chromatin accessibility at pro-inflammatory gene loci, contributing to immunoparalysis. Conversely, certain loci related to tissue repair become more accessible, reflecting a dynamic and context-dependent epigenetic landscape. These changes are not merely passive but actively shape the transcriptomic and functional responses of cells during critical illness.
Several risk factors modulate the extent and pattern of chromatin accessibility changes during critical illness. These include age, pre-existing comorbidities (such as diabetes or chronic inflammatory conditions), genetic polymorphisms in chromatin regulators, and the severity and duration of the inciting insult. Notably, elderly patients exhibit a distinct chromatin accessibility signature characterized by reduced plasticity and impaired resolution of inflammation, correlating with poorer outcomes. Environmental exposures, medication history, and nutritional status may also influence the epigenetic response to critical illness, underscoring the complexity of host-environment interactions.
While chromatin accessibility changes are not directly observable at the bedside, they underpin many clinical features of critical illness, such as immune suppression, persistent inflammation, and maladaptive tissue responses. For instance, the transition from a hyperinflammatory to an immunosuppressed phenotype in sepsis is mediated in part by chromatin condensation at key cytokine gene loci. These epigenetic alterations contribute to increased susceptibility to secondary infections, delayed wound healing, and prolonged organ dysfunction. Recent studies suggest that persistent changes in chromatin state may underlie the syndrome of post-intensive care syndrome (PICS), manifesting as cognitive, psychological, and physical impairments in survivors.
Current diagnostic approaches for critical illness focus on clinical scoring systems and biomarkers of inflammation and organ function. However, emerging technologies such as ATAC-seq (assay for transposase-accessible chromatin sequencing) and single-cell epigenomics now enable the assessment of chromatin accessibility in patient-derived samples. These techniques can identify disease-specific epigenetic signatures and may serve as next-generation biomarkers for risk stratification, prognosis, and therapeutic response. Integration of chromatin accessibility data with transcriptomic and proteomic profiles holds promise for a more comprehensive, systems-level approach to critical illness diagnostics.
Current management of critical illness is largely supportive, targeting underlying causes and preventing complications. However, recognition of the role of chromatin remodeling in disease progression has spurred interest in epigenetic therapies. Agents targeting histone deacetylases (HDACs) or bromodomain proteins, which modulate chromatin structure and function, are being explored in preclinical models of sepsis and ARDS. Adjunctive therapies aimed at restoring balanced chromatin accessibility may enhance immune function, promote tissue repair, and improve survival. Optimization of supportive care—nutrition, glycemic control, and infection prevention—may also favorably influence the epigenetic landscape.
Recent years have witnessed rapid advances in understanding and manipulating chromatin accessibility during critical illness. High-resolution single-cell ATAC-seq has unveiled cell-specific epigenetic trajectories and identified novel regulators of immune dysfunction. Preclinical studies using HDAC inhibitors or BET bromodomain inhibitors have shown promise in reversing immunosuppression and improving outcomes in animal models of sepsis. Clinical trials are underway to evaluate the safety and efficacy of these agents in human critical illness. Furthermore, CRISPR-based epigenome editing offers the potential for targeted modulation of chromatin accessibility at disease-relevant loci, heralding a new era of precision epigenetic therapeutics.
While major critical care guidelines currently do not include specific recommendations on the assessment or modulation of chromatin accessibility, there is growing recognition of the need to incorporate epigenetic insights into clinical practice. Consensus statements emphasize the importance of translational research to validate chromatin-based biomarkers and therapies. Experts advocate for multidisciplinary collaboration between intensivists, geneticists, and molecular biologists to accelerate the integration of epigenetic diagnostics and interventions into standard care protocols. Ongoing updates to guidelines are anticipated as evidence accumulates from clinical trials and real-world studies.
Chromatin accessibility changes represent a fundamental mechanism underpinning the host response to critical illness, shaping clinical trajectories and outcomes. Advances in epigenomic technologies have illuminated the complexity and plasticity of these changes, opening new avenues for biomarker discovery and targeted therapy. Continued research is essential to translate these insights into clinical practice and improve the care of critically ill patients. As our understanding of the epigenetic landscape deepens, precision medicine approaches tailored to individual chromatin profiles may become a cornerstone of critical care management.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation